21st World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC)

21st World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) is organized by The Metabolic Institute of America (TMIOA) and will be held from Dec 07 - 09, 2023 at Hilton Los Angeles/Universal City, Universal City, California, United States of America.

Program Description
The World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC), now in its 21st year, is a unique and exciting multidisciplinary CME conference. The Congress has become the premier global meeting dedicated to diabetes, obesity, lipids, cardiovascular-kidney, and liver disease linking basic research to clinical practice in pursuit of our theme: Exploring New Frontiers in Metabolism — Tomorrow’s Clinical Science Today.

Program Objectives

• The program is designed to evaluate the clinical and basic science aspects of diabetes.
• The program is designed to evaluate both clinical and basic science aspects of diabetes, obesity, CVD, and CKD, focusing on insulin resistance, incretins, the gut, the brain, the kidney, and the heart.
• The goal is to understand the pathophysiology and develop appropriate comprehensive clinical management plans.

Upon completion of this meeting, participants should be able to:

• Describe the relationship between diabetes, obesity, kidney disease, and heart disease
• Implement best practices for the prevention and management of CKD, HF, and CVD
• Describe the recommended uses of SGLT2 inhibitors for the treatment of HF
• Understand the contemporary role of SGLT2 inhibitors in CKD with and without diabetes
• Describe the benefits of GLP1-RAs in patients with ASCVD or at risk of ASCVD events
• Evaluate the evidence supporting the use of new and emerging therapies to reduce cardiovascular mortality in patients with cardiometabolic disease
• Explain the roles of diabetes and insulin resistance in the development of CKD, HF, and CVD
• Evaluate the impact on the clinical practice of new CVOTs in patients with diabetes and cardiometabolic diseases
• Discuss the effects of insulin resistance on the heart, kidney, and liver
• Design therapeutic regimens for patients with multiple cardiometabolic and renal disorders that capitalize on agents with broad effects across the spectrum of these comorbidities
• Utilize technology to enhance the effectiveness of therapeutics
• Describe the direct and indirect impact of the COVID-19 pandemic on patient health